Jyothi Manohar
A5009449037- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Phagocytosis and Immune Regulation
- Iron Metabolism and Disorders
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Erythropoietin and Anemia Treatment
- Biotechnology and Related Fields
- MicroRNA in disease regulation
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Reproductive System and Pregnancy
- Epigenetics and DNA Methylation
- BRCA gene mutations in cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Extracellular vesicles in disease
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- DNA Repair Mechanisms
Weill Cornell Medicine
2019-2025
Cornell University
2019-2025
Precision for Medicine (United States)
2019-2025
Lander Institute
2020-2024
SRM University
2024
Texas Health Dallas
2020-2023
NewYork–Presbyterian Hospital
2021
New York Hospital Queens
2021
University of Michigan
2019
Abstract Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic screens. Most...
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity
Several reports describing a rare primary liver tumor with histologic features reminiscent of follicular thyroid neoplasms have been published under variety descriptive terms including thyroid-like, solid tubulocystic, and cholangioblastic cholangiocarcinoma. Although these tumors are considered to represent variants, they lack classic cholangiocarcinoma unique characteristics, namely immunoreactivity for inhibin NIPBL::NACC1 fusions. The purpose this study is present clinicopathologic...
Abstract Iron accumulation in tumors contributes to disease progression and chemoresistance. Although targeting this process can influence various hallmarks of cancer, the immunomodulatory effects iron chelation tumor microenvironment are unknown. Here, we report that treatment with deferiprone, an FDA-approved chelator, unleashes innate immune responses restrain ovarian cancer. Deferiprone reprogrammed cancer cells toward immunostimulatory state characterized by production type-I IFN...
Abstract Neuroendocrine prostate cancer is an aggressive variant of that may arise de novo or develop from pre-existing adenocarcinoma as a mechanism treatment resistance. The combined loss tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present subset adenocarcinomas. Most clinical preclinical studies support trans-differentiation process, whereby arises clonally precursor during the course Here we highlight case with significant intra-patient heterogeneity observed...
Abstract The molecular characteristics of metastatic upper tract urothelial carcinoma (UTUC) are not well understood, and there is a lack knowledge regarding the genomic transcriptomic differences between primary UTUC. To address these gaps, we integrate whole-exome sequencing, RNA Imaging Mass Cytometry using lanthanide metal-conjugated antibodies 44 tumor samples from 28 patients with high-grade We perform spatially-resolved single-cell analysis cancer, immune, stromal cells to understand...
<p>PDTOs breast cancer subtype analysis</p>
<p>IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.</p>
<p>List of raw gRNA counts</p>
<p>List of primers and vectors used in this study.</p>
<p>List of inhibitors tested in HTDS alone or combination with gefitinib.</p>
<p>PDTO breast media composition.</p>
<p>Patient clinical information</p>
<div>Abstract<p>Precision medicine approaches to cancer treatment aim exploit genomic alterations that are specific individual patients tailor therapeutic strategies. Yet, some targetable genes and pathways essential for tumor cell viability even in the absence of direct alterations. In underrepresented populations, mutational landscape determinants response existing therapies poorly characterized because limited inclusion clinical trials studies. One way reveal is with genetic...
<p>Supplementary Figures 1-7</p>
<p>Table S4 describes the organoids used in this study</p>
<p>Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination cisplatin. S3. (a-f) Wild-type female implanted ID8-Defb29/Vegfa and described Fig 2 d. S4. Representative images NKp46 staining entire omentum. S5. MTT assays ID8-Defb29/Vegfa, PPNM, MP different concentrations 12, 24, 48...
<p>Table S3 contains all statistically significant DEGs from RNAseq data</p>
<p>Table S2 contains all the information related to mass spectrometry</p>
<p>Table S5 contains all the primers used in this study</p>
<p>Table S1 describes all the human ascites samples analyzed</p>